Roche Ends Agreement With Repare Therapeutics to Develop ATR Inhibitor Camonsertib

Roche halts agreement with Repare Therapeutics to develop and commercialize camonsertib just weeks after triggering a $40 million milestone payment when the first patient was dosed with the novel cancer drug.

Source link
#Roche #Ends #Agreement #Repare #Therapeutics #Develop #ATR #Inhibitor #Camonsertib